Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-11-16
2004-08-10
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S153000, C546S155000, C546S157000
Reexamination Certificate
active
06774134
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention concerns antiviral compounds, their methods of preparation and their compositions, and use in the treatment of viral infections. More particularly, the invention provides heterocyclic substituted 2-methylbenzimidazole derivatives for the treatment of respiratory syncytial virus infection.
2. Background Art
Respiratory syncytial virus (RSV) is the leading cause of serious lower respiratory tract infection in infants, children, elderly and immunocompromised persons. A severe viral infection may result in bronchiolitis or pneumonia which may require hospitalization or result in death. (
JAMA
, 1997, 277, 12). Currently only Ribavirin is approved for the treatment of this viral infection. Ribavirin is a nucleoside analogue which is administered intranasally as an aerosol. The agent is quite toxic, and its efficacy has remained controversial. RespiGam, approved for prophylaxis in high risk pediatric patients, is an intravenous immunoglobulin which effectively neutralizes the virus. Recently, Synagis, a monoclonal antibody administered through intramuscular injection has also been approved for use in high risk pediatric patients. However, both drugs are very expensive. Accordingly, inexpensive, safe and effective antiviral agents against respiratory syncytial virus will be beneficial for patients.
Many agents are known to inhibit respiratory syncytial virus (De Clercq,
Int. J. Antiviral Agents
, 1996, 7, 193). Y. Tao et al. (EP 0 058 146 A1, 1998) disclosed that Ceterizine, a known antihistamine, exhibited anti-RSV activity. Tidwell et al.,
J. Med. Chem
. 1983, 26, 294 (U.S. Pat. No. 4,324,794, 1982), and Dubovi et al.,
Antimicrobial Agents and Chemotherapy
, 1981, 19, 649, reported a series of amidino compounds with the formula shown below as inhibitors of RSV.
Hsu et al., U.S. Pat. No. 5,256,668 (1993) also disclosed a series of 6-aminopyrimidones that possess anti-viral activity against RSV.
Y. Gluzman, et al., (AU Patent, Au-A-14,704, 1997) and P. R. Wyde et al. (
Antiviral Res
. 1998, 38, 31) disclosed a series of triazine containing compounds that were useful for the treatment and/or prevention of RSV infection.
In addition, T. Nitz, et al., (WO Patent, WO 00/38508, 1999) disclosed a series of triaryl containing compounds that were useful for the treatment and/or prevention of RSV and related pneumoviral infections.
Moreover, Yu et al. (WO 020004900) also disclosed a series of substituted benzimidazoles that is useful for the treatment and prevention of RSV infection.
A related series of compounds were first disclosed by F. Pagani and F. Sparatore in
Boll Chim Farm
. 1965, 104, 427 and by G. Paglietti, et al. in
Il Farmaco, Ed. Sci
. 1975, 30, 505, and found to possess analgesic and anti-arrhythmic activity. The structural formula for these compounds are depicted in Formula Ia and Ib.
In Formula Ia and Ib, A is —(CH
2
)n-N(R)
2
, n=2 or 3, R=Me or Et, or A is
B=H, Cl, CF
3
, CH
3
CO, NO
2
.
Another series of closely related compounds that Sparatore had disclosed were in
Il Farmaco Ed. Sci
. 1967, 23, 344 (U.S. Pat. No. 3,394,141, 1968). Some of the compounds were reported to have analgesic, anti-inflammatory or anti-pyretic activities. The structure of these compounds is depicted in Formula Ic. In Formula Ic, C=H, CF
3
, or NO
2
. D is —(CH
2
)n-NR
2
, n=2 or 3, R=Me or Et, or D=
E is H, Cl or OEt.
Another series of compounds structurally related to this invention are pyrido[1,2-a]benzoazoles and pyrimidio[1,2a]benzimidazoles disclosed by S. Shigeta et al in
Antiviral Chem
. &
Chemother
. 1992, 3, 171. These compounds have demonstrated inhibition of orthomyxovirus and paramyxovirus replication in HeLa cells. The structures of these compounds are shown in Formulas Id and Ie, in which F=NH, S, or O; Q=—NHCOPh, —COOH, COOEt, or CN; T=COMe, CN, or COOEt; G=O or NH.
A bis-benzimidazole with an ethylenediol linker shown below has also been reported as a potent inhibitor of rhinoviruses (Roderick, et al.
J. Med. Chem
. 1972, 15, 655).
A series of 2-aminobenzimidazoles have been reported by E. Janssens, et al. as inhibitors of RSV in a series of recent publications and representative examples formula 1f-1h are shown below from PCT WO 01/00611 A1; PCT WO 01/00612 and PCT WO 01/00615, respectively all published on Jan. 4, 2001.
A series of triazole containing compounds have been reported by Janssen as inhibitors of RSV in PCT WO 01/36395 (May 25, 2001) and a representative example is shown below.
Other structurally related compounds are bis-benzimidazoles which possess antifungal activity (B. Cakir, et al.
Eczacilik Fak. Derg
. 1988, 5, 71).
Also, H. R. Howard et al. reported a series of benzimidazolone-1-acetic acids that possessed aldolase reductase inhibitory activity (
Eur. J. Med. Chem
. 1992, 27, 779-789).
Other prior art related to the chemical structure of the present invention:
(1) F. Sparatore, et al, “Derivati Benzotriazolici Attivi Sull'accrescimento Delle Piante,”
Il Farmaco Ed. Sci
. 1978, 33, 901.
(2) Katritzky, A. R. et al, “Synthesis and Transformations Of Substituted Benzazolyl- and Tetrazolyl(benzotriazol-1-yl)methanes,”
J. Heterocyclic Chem
. 1996, 33, 1107.
(3) Terri A. Fairley, et al. “Structure, DNA Minor Groove Binding, And Base Pair Specificity of Alkyl and Aryl-Linked Bis(amidinobenzimidazoles) and Bis(amidinoindoles),
J. Med. Chem
. 1993, 36, 1746.
(4) R. K. Upadhyay et al, “New Synthesis and Biological Evaluation,”
Indian J. Heterocyclic Chem
. 1994, 4, 121.
(5) A. R. Katritzky, et al, “A New Route to N-substituted Heterocycles,”
Tetrahedron
, 1993, 49, 2829.
(6) K. Yu et al. in Substituted Benzimidazole Anti-viral Agents, PCT WO00/04900 published Feb. 3, 2000.
SUMMARY OF THE INVENTION
This invention relates to novel heterocyclic substituted 2-methylbenzimidazoles and the antiviral activity against RSV. The structural formula for these compounds are depicted in Formula I, and includes pharmaceutically acceptable salts thereof,
wherein:
R
1
is —(CR
a
R
b
)
n
—X;
R
a
, R
b
are each independently selected from the group consisting of H, C
1-6
alkyl; each of said C
1-6
alkyl being optionally substituted with one to six same or different halogen;
X is H or C
1-6
alkyl; said C
1-6
alkyl being optionally substituted with a member selected from the group consisting of (1) one to six same or different halogen or hydroxy, (2) heteroaryl, (3) non-aromatic heterocyclic ring and (4) a member selected from Group A;
n is 1-6;
Group A is a member selected from the group consisting of halogen, CN, OR
x
,
N
+
R
c
R
d
R
e
[T
−
], NR
c
R
d
, COR
c
, CO
2
R
x
, CONR
x
R
y
and S(O)
m
R
c
;
R
x
and R
y
are independently H or C
1-6
alkyl;
R
c
, R
d
and R
e
are independently C
1-6
alkyl;
m is 0-2
T
−
is halogen, CF
3
SO
3
−
or CH
3
SO
3
−
;
R
2
and R
5
are independently halogen or H;
R
3
and R
4
are each independently selected from the group consisting of H, halogen and C
1-6
alkyl; said C
1-6
alkyl can be optionally substituted with one to six same or different halogen;
Q is a member selected from the group consisting of
R
6
is selected from the group consisting of H, halogen, NR
f
R
g
, SR
n
and a five-membered heteroaryl containing one to two of the same or different heteroatoms selected from the group consisting of O, S and N;
R
f
and R
g
are independently H, C
1-6
alkyl or C
1-6
alkyl; said C
1-6
alkyl optionally substituted with OR
h
or CO
2
R
h
;
R
h
and R
i
are independently H or C
1-6
alkyl;
R
n
is C
1-6
alkyl optionally substituted with CO
2
R
h
;
R
7
is H, or CO
2
R
h
;
R
8
is H, COR
h
, CO
2
R
h
or C
1-6
alkyl; said C
1-6
alkyl optionally substituted with OR
h
;
R
9
is H, halogen, heteroaryl, phenyl, phenyl substituted with a halogen group, phenyl substituted with a methanesulfonyl group, COR
h
, CO
2
R
h
, C
1-6
alkyl, C
2-6
alkenyl, and C
2-4
alkynyl; said C
2-4
alkynyl optionally su
Civiello Rita L.
Combrink Keith D.
Gulgeze Hatice Belgin
Meanwell Nicholas
Pearce Bradley C.
Anderson Rebecca
Bristol--Myers Squibb Company
DuBoff Samuel J.
McKane Joseph K.
LandOfFree
Heterocyclic substituted 2-methyl-benzimidazole antiviral... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic substituted 2-methyl-benzimidazole antiviral..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic substituted 2-methyl-benzimidazole antiviral... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3274059